1. Introduction

Restrictions on foreign-owned genetic material concern the legal rules governing the collection, ownership, possession, transfer, export, import, research, commercialisation and cross-border use of genetic resources by foreign individuals, companies, universities, laboratories and biotechnology organisations.

Genetic material includes:

Human DNA, RNA, cells, tissues and biological samples.

Plant genetic resources, seeds and medicinal plants.

Animal genetic material, embryos and reproductive cells.

Microorganisms, bacteria, viruses and other biological resources.

Genetic sequences and associated digital sequence information (DSI).

Biologically derived materials used in pharmaceutical and biotechnology research.

The central legal question is whether a foreign person or organisation can acquire, control, use or commercially exploit genetic material originating in another country.

International law generally does not establish one universal ownership rule. Instead, national sovereignty, biodiversity conservation, human rights, research ethics, intellectual property, biosecurity and access-and-benefit-sharing obligations operate together.

The fundamental principle is that possession of a biological sample does not automatically confer unrestricted ownership or permission to exploit its genetic information.

2. Legal foundations of restrictions

The principal legal foundations include:

A. National sovereignty over genetic resources

States exercise sovereign rights over their natural resources, including genetic resources within their jurisdiction. They may regulate foreign access, research permits, collection activities and export.

B. Prior informed consent (PIC)

Foreign researchers may need permission from the competent national authority or other legally recognised providers before collecting or accessing genetic resources.

C. Mutually agreed terms (MAT)

Access agreements may establish conditions concerning:

Permitted scientific research.

Export and transfer restrictions.

Commercial development.

Publication and intellectual property.

Sharing of research results.

Financial and non-financial benefits.

Return or destruction of biological samples.

D. Access and benefit sharing (ABS)

Foreign companies and researchers may be required to share benefits arising from the utilisation of genetic resources with the country or recognised provider supplying them.

E. Human genetic privacy

Human genetic material raises additional issues involving informed consent, confidentiality, genetic discrimination, bodily autonomy and protection of personal information.

3. International legal framework

A. Convention on Biological Diversity, 1992 (CBD)

The Convention on Biological Diversity is the foundational international instrument regulating access to genetic resources.

Article 15 recognises the sovereign rights of states over their natural resources. Consequently, national governments have authority to determine access to genetic resources under domestic legislation.

Its principal requirements include:

Access to genetic resources must comply with national legislation.

Prior informed consent may be required from the providing country.

Access must be based on mutually agreed terms.

Benefits arising from research and commercial utilisation should be shared fairly.

Scientific cooperation and technology transfer should be encouraged.

Legal significance: A foreign biotechnology company cannot assume that genetic resources are freely available merely because it can physically collect, purchase or transport them.

InforMEA+1

B. Nagoya Protocol, 2010

The Nagoya Protocol strengthens the CBD framework through access and benefit-sharing obligations.

Its important provisions are:

Article 6 is particularly important because it allows countries to regulate foreign access to their genetic resources through national permission systems.

Article 17 provides for monitoring and internationally recognised certificates of compliance.

For example, a foreign pharmaceutical company seeking to investigate a medicinal plant collected from another country may need to establish that the collection was lawful, that the relevant permissions were obtained and that benefit-sharing conditions have been satisfied.

Convention on Biological Diversity+2

C. International Treaty on Plant Genetic Resources for Food and Agriculture, 2001

The International Treaty on Plant Genetic Resources for Food and Agriculture establishes a specialised system for access to certain plant genetic resources used for food and agriculture.

Its Multilateral System facilitates access to specified plant genetic materials for research, breeding and training.

The Standard Material Transfer Agreement (SMTA) regulates transfers and establishes benefit-sharing obligations.

A foreign seed company receiving genetic material under this system cannot disregard the contractual restrictions governing subsequent transfers and commercial utilisation.

FAO+1

4. Major restrictions on foreign ownership and control

A. Restrictions on acquisition

A foreign organisation may be prohibited from acquiring genetic material without appropriate authorisation.

Governments may require:

Collection permits.

Research authorisations.

Import and export permissions.

Environmental clearances.

Approval from biodiversity authorities.

Agreements with recognised local communities.

Unauthorised collection may result in administrative penalties, confiscation, cancellation of permissions or other remedies under domestic law.

B. Restrictions on transfer of genetic samples

A foreign institution may receive biological samples for a narrowly defined research purpose.

However, permission to receive a sample does not necessarily permit its subsequent transfer to another company, laboratory or country.

For example, a university may receive plant tissue for non-commercial research but may be prohibited from transferring it to a foreign pharmaceutical company without additional approval.

The relevant material transfer agreement should specify:

Identity of the receiving institution.

Permitted research activities.

Geographic restrictions.

Subsequent transfer conditions.

Commercialisation restrictions.

Duration of possession.

Return or destruction obligations.

C. Restrictions on commercial exploitation

Commercial exploitation creates particularly important legal issues.

Foreign organisations may be required to obtain additional approvals before developing:

Pharmaceutical products.

Genetically modified crops.

Biological medicines.

Industrial enzymes.

Diagnostic products.

Commercially valuable genetic technologies.

A research permission should not automatically be interpreted as permission for commercial manufacturing, patent licensing or commercial distribution.

The Nagoya Protocol's benefit-sharing framework is particularly relevant where the utilisation of genetic resources generates commercial benefits.

D. Restrictions on foreign corporate ownership

Some national laws distinguish between domestic and foreign-controlled entities.

They may regulate:

Foreign shareholding in biotechnology companies.

Foreign control over genetic-resource repositories.

Acquisition of biological-resource businesses.

Overseas ownership of research infrastructure.

Foreign access to strategically important biological collections.

These restrictions are jurisdiction-specific. The CBD does not itself establish a universal prohibition on foreign ownership of biotechnology companies or genetic samples.

E. Restrictions concerning indigenous and local communities

Genetic resources may be associated with traditional medicinal knowledge, indigenous agricultural practices and community-developed biological knowledge.

Article 7 of the Nagoya Protocol requires appropriate protection through prior informed consent or approval and involvement of communities, in accordance with domestic law.

Foreign companies must therefore consider whether a national authority's permission alone is sufficient or whether separate community consent and benefit-sharing arrangements are required.

5. Human genetic material and foreign ownership

Human genetic material requires a separate legal analysis from biodiversity-based genetic resources.

Human DNA, tissues, embryos, blood samples and reproductive materials raise questions concerning:

Bodily autonomy.

Informed consent.

Privacy and confidentiality.

Ownership of stored biological samples.

Commercial use of donated tissues.

International transfer of genomic information.

Research involving vulnerable populations.

A foreign university may receive human biological samples for research, but its legal authority depends on the consent documents, applicable research laws, privacy requirements and transfer agreements.

Important distinction: The Nagoya Protocol's framework for genetic resources should not automatically be applied to human genetic material. Human genetic resources are not treated as ordinary biodiversity resources under this framework.

Foreign ownership of a physical sample, rights over derived research results and rights over identifiable genetic information are three separate legal questions.

6. Restrictions on genetic information and digital sequence data

Modern biotechnology makes it possible to obtain genetic information without physically exporting the original biological material.

For example, a researcher may sequence a plant's genome locally and send the digital sequence to a foreign pharmaceutical company.

This raises the question of whether digital sequence information (DSI) should be subject to benefit-sharing requirements even when the physical sample remains in its country of origin.

The international debate is particularly important because genetic information can be copied, stored, analysed and transferred internationally with little physical movement.

The CBD's COP16 decisions in 2024 established the Cali Fund framework for benefit-sharing from the use of DSI, including contributions from relevant commercial users in accordance with the adopted arrangements.

This development demonstrates that restrictions on foreign exploitation increasingly concern genetic information, not merely physical samples.

7. Important case laws and judicial interpretation

The following cases are particularly useful for understanding restrictions on genetic material, biological sample ownership, research consent and benefit-sharing.

Case 1. Moore v. Regents of the University of California (1990)

Citation: 51 Cal. 3d 120; 793 P.2d 479.

Facts:

John Moore received medical treatment for leukaemia. His physician discovered that Moore's cells had unusual scientific and commercial potential.

The physician used the cells in research and developed a commercially valuable cell line without adequately disclosing his research and economic interests to Moore.

Moore challenged the conduct, claiming that his biological material had been used without proper consent.

Legal issues:

Whether patients retain ownership of removed human cells.

Whether doctors must disclose commercial research interests.

Whether unauthorised use of genetic material amounts to conversion.

Judgment:

The California Supreme Court held that Moore could pursue claims for breach of fiduciary duty and lack of informed consent.

However, it rejected his conversion claim based on ownership of the removed cells.

Legal principle:

The decision distinguishes between ownership of biological material and the right to informed consent concerning its use.

Relevance to foreign ownership:

A foreign research institution cannot assume that possession of human genetic material gives it unrestricted ethical or legal authority to exploit the material.

The case is particularly important when foreign biotechnology organisations obtain human tissues through hospitals, medical research institutions or international research collaborations.

Justia Law+1

Case 2. Greenberg v. Miami Children's Hospital Research Institute (2003)

Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003).

Facts:

Families affected by Canavan disease supplied blood and tissue samples, information and financial support to assist genetic research.

Researchers successfully identified the disease-associated gene and subsequently obtained a patent.

The research institution later pursued restrictive licensing arrangements and commercial control over the relevant technology.

The donors argued that the research benefits had been commercially exploited without respecting their expectations.

Legal issues:

Commercial exploitation of donated genetic samples.

Donor expectations and research collaboration.

Unjust enrichment.

Ownership and control of genetic research outcomes.

Judgment:

The court dismissed several claims, including conversion and certain informed-consent and fiduciary-duty claims.

However, it allowed the unjust-enrichment claim to proceed because the allegations described an ongoing research collaboration in which donors had contributed substantial resources.

Legal principle:

Even where researchers have legally obtained biological samples, their subsequent conduct may create independent obligations under applicable contractual or equitable principles.

Relevance to foreign ownership:

Foreign research institutions should clearly disclose commercial intentions, intellectual property arrangements and the anticipated uses of donated genetic materials.

PubMed+2

Case 3. Washington University v. Catalona (2007)

Citation: 490 F.3d 667 (8th Cir. 2007).

Facts:

Patients donated blood and tissue samples for prostate cancer research at Washington University.

A researcher who subsequently left the university sought to transfer the samples to his new institution.

The university claimed ownership of the biological materials.

Legal issue:

Whether donors or the departing researcher could direct the transfer of donated biological samples to another research institution.

Judgment:

The United States Court of Appeals for the Eighth Circuit upheld the university's ownership of the samples.

The court found that the donors had made informed and voluntary donations to the university under the circumstances of the case.

Legal principle:

Ownership and transfer rights concerning donated biological materials may depend on the donation documents, the receiving institution's rights and the applicable law.

Relevance to foreign ownership:

A foreign institution receiving biological samples must examine the original consent documents and transfer conditions. A researcher cannot necessarily transfer samples merely because they personally collected or studied them.

law.justia.com+1

Case 4. Divya Pharmacy v. Union of India (2018)

Citation: 2018 SCC OnLine Utt 1035; W.P. (M/S) No. 3437 of 2016.

Court: Uttarakhand High Court, India.

Facts:

Divya Pharmacy challenged demands for fair and equitable benefit-sharing arising from its commercial use of biological resources.

It argued that the relevant obligations should not apply to an Indian entity without foreign participation.

Legal issue:

Whether an Indian commercial entity using biological resources could be required to share benefits even without foreign ownership or participation.

Judgment:

The High Court rejected the challenge and upheld the applicability of benefit-sharing obligations to the petitioner under the Indian Biological Diversity Act, 2002.

Legal principle:

Benefit-sharing is not necessarily limited to foreign companies. Domestic commercial utilisation of biological resources may also attract statutory obligations.

Relevance to foreign ownership:

This decision demonstrates that the legal regulation of genetic and biological resources is not confined to foreign ownership. The nature of the resource, commercial utilisation and statutory benefit-sharing framework are also relevant.

abs.nls.ac.in+2

Case 5. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Citation: 569 U.S. 576 (2013).

Facts:

Myriad Genetics claimed patent rights over isolated DNA sequences associated with breast and ovarian cancer, particularly BRCA1 and BRCA2.

The dispute concerned whether naturally occurring human genetic material could be patented merely because it had been isolated.

Legal issue:

Whether naturally occurring DNA sequences were patentable inventions.

Judgment:

The United States Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated.

However, synthetically created complementary DNA (cDNA) may be patent-eligible, subject to the applicable legal requirements and exceptions.

Legal principle:

Discovering and isolating naturally occurring genetic material does not automatically create an exclusive patent right over that material.

Relevance to foreign ownership:

A foreign biotechnology company cannot automatically claim exclusive intellectual property rights over naturally occurring genetic sequences obtained from another country.

The case distinguishes ownership of biological samples from patent rights over genuinely inventive technological developments.

California Supreme Court Resources

8. Indian legal framework governing foreign-owned genetic material

India provides an important example of a national regulatory system controlling access to biological resources.

The principal legislation is the Biological Diversity Act, 2002.

Its regulatory framework includes the National Biodiversity Authority (NBA), State Biodiversity Boards and Biodiversity Management Committees.

The principal statutory provisions include:

Foreign ownership implications:

Foreign individuals and certain foreign-controlled or foreign-participated entities fall within the restrictions under Section 3.

Prior approval from the National Biodiversity Authority may be required for covered access to Indian biological resources.

Certain transfers of research results are regulated under Section 4.

Intellectual property applications involving Indian biological resources are subject to the applicable statutory approval requirements.

Benefit-sharing obligations may apply to commercial utilisation.

Non-compliance can result in statutory enforcement action.

The exact application of these provisions depends on the entity's legal status, the biological resource, the nature of the proposed activity and applicable exemptions.

Important distinction: Section 3 regulates specified foreign connections; it does not establish that every foreign investment in an Indian biotechnology company is automatically prohibited.

The Divya Pharmacy decision also demonstrates that benefit-sharing obligations can extend to domestic commercial entities.

abs.nls.ac.in+2

9. Legal challenges involving foreign-owned genetic material

Several recurring legal problems arise in international biotechnology transactions.

A. Unauthorised export

A foreign organisation may export biological samples without obtaining the necessary domestic authorisation.

This may result in:

Seizure of biological samples.

Suspension of research activities.

Administrative penalties.

Criminal prosecution where provided by law.

Orders for return or destruction of materials.

B. Disputes over ownership

A dispute may arise between a donor, research institution, foreign laboratory and biotechnology company over who owns biological samples.

The outcome generally depends on the applicable property law, donation agreement, informed-consent documents and statutory restrictions.

C. Unauthorised patent applications

A foreign company may attempt to obtain intellectual property protection based on genetic material acquired from another country.

Such disputes may involve:

Lack of lawful access.

Failure to comply with benefit-sharing conditions.

Misappropriation of traditional knowledge.

Patent eligibility.

Breach of material transfer agreements.

D. Commercialisation without benefit-sharing

A foreign pharmaceutical company may develop a commercial product using genetic resources obtained from a developing country without complying with applicable benefit-sharing requirements.

This can lead to regulatory proceedings, contractual disputes and demands for compensation.

E. Conflicts between national laws

A biological sample may be lawfully collected in one country but transferred to another country with stricter import, research or privacy requirements.

This creates jurisdictional conflicts concerning:

Applicable law.

Validity of consent.

Recognition of permits.

Ownership rights.

Enforcement of contractual restrictions.

International cooperation between regulatory authorities.

10. Responsibilities of foreign biotechnology companies

Foreign biotechnology companies should adopt a comprehensive compliance programme.

11. Remedies and enforcement mechanisms

Governments and affected communities may use different legal remedies to address violations involving foreign-owned genetic material.

1. Administrative remedies

Authorities may suspend research approvals, cancel permits or prohibit further access.

2. Civil remedies

Affected parties may seek compensation, contractual damages, restitution or injunctions.

3. Criminal remedies

Criminal liability may arise where domestic legislation criminalises unauthorised collection, export, misappropriation or other prohibited conduct.

4. Intellectual property remedies

Patent applications may be challenged or patents opposed where the relevant legal requirements are not satisfied.

5. International dispute resolution

Disputes may be resolved through negotiation, mediation, arbitration or domestic judicial proceedings, depending on the applicable agreements and legal framework.

12. Critical legal analysis

Restrictions on foreign-owned genetic material involve a difficult balance between national sovereignty and international scientific cooperation.

Excessively restrictive laws can discourage scientific collaboration, delay medical discoveries and prevent developing countries from accessing advanced biotechnology.

On the other hand, unrestricted foreign acquisition may encourage exploitation of biological resources, unequal commercial arrangements and misappropriation of indigenous knowledge.

Five major challenges deserve particular attention:

Ownership uncertainty: Different jurisdictions recognise different rights over biological samples and their derivatives.

Digital sequence information: Genetic information can move internationally without transferring physical samples.

Benefit-sharing enforcement: It can be difficult to identify and monitor every commercial use of genetic resources.

Indigenous community protection: National permission does not always resolve questions about community rights and traditional knowledge.

International jurisdiction: Foreign companies may operate through subsidiaries, research partners and overseas laboratories, complicating enforcement.

A sound legal framework should therefore distinguish between physical ownership, permission to conduct research, rights over genetic information and commercial intellectual property.

13. Conclusion

Restrictions on foreign-owned genetic material are an essential component of modern biotechnology governance.

The Convention on Biological Diversity and the Nagoya Protocol establish important principles of national sovereignty, prior informed consent and fair benefit-sharing. National legislation determines how those principles apply to actual collection, transfer and commercialisation activities.

Judicial decisions such as Moore, Greenberg, Washington University v. Catalona and Divya Pharmacy demonstrate that biological sample ownership, informed consent, institutional control and benefit-sharing are distinct legal questions.

Ultimately, foreign ownership should not be confused with unrestricted authority to collect, transfer, research or commercialise genetic resources. Effective regulation requires lawful access, transparent agreements, protection of human and community interests, and enforceable benefit-sharing arrangements.

14. Important authorities for further legal research

Additional case reference: Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). The Supreme Court distinguished naturally occurring DNA from synthetically created cDNA for patent eligibility under US law.

Justia U.S. Supreme Court Center+1

Research note: These cases arise under different national legal systems. They are comparative authorities, not a single binding international precedent. For a legal opinion, the law of the country where the genetic material originated, the country where it is held and the country where it will be used must be examined separately.

I can also prepare this subject as an India-specific legal research chapter with statutory provisions, recent amendments, regulatory authorities and additional Indian case laws.